Last reviewed · How we verify
NCT06610487
A Study of FT1 in Healthy Adult Volunteers
Phase 1 trial testing FT1 in Diarrhea Caused by Drug (Disorder) in 60 participants. Completed in 8 August 2025.
8 August 2025
Quick facts
| Lead sponsor | Chongqing Peg-Bio Biopharm Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 20 August 2024 |
| Primary completion | 8 August 2025 |
| Estimated completion | 8 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- FT1 — full drug profile →
- Placebo
Conditions studied
- Diarrhea Caused by Drug (Disorder) — all drugs for Diarrhea Caused by Drug (Disorder) →
Sponsor
Chongqing Peg-Bio Biopharm Co., Ltd. — full company profile →
Who can join
Adults 18 to 45, any sex, with Diarrhea Caused by Drug (Disorder). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main aim of this clinical trial is to assess the safety of FT1 in participants aged 18 to 45 years. The main questions it aims to answer are: • Is FT1 safe in healthy adults? Researchers will compare FT1 to a placebo (a look-alike substance that contains no drug) to see if FT1 is safe and active in human. Participants will * Receive one subcutaneous injection or multiple injections of FT1 or placebo according to weight. * Visit the clinic for assessment.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
Verify or expand the search:
- PubMed search for NCT06610487
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Chongqing Peg-Bio Biopharm Co., Ltd. trials
Trials by the same sponsor.
- NCT07446491 — A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver · Phase 1, PHASE2 · recruiting
- NCT06880081 — Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) · Phase 1 · recruiting
- NCT06512584 — Efficacy and Safety of PJ009 in Patients With Short Bowel Syndrome Requiring Parenteral Nutrition · Phase 3 · recruiting
- NCT06521931 — A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients · Phase 1 · completed
- NCT06527781 — A Study of PD5K3 in Healthy Adult Volunteers · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06610487 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chongqing Peg-Bio Biopharm Co., Ltd.
- Last refreshed: 2 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06610487.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing